Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for AVITA Medical (RCEL) over the last 7 years, with Q4 2025 value amounting to $20000.0.

  • AVITA Medical's Other Non Operating Income rose 10934.58% to $20000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.0 million, marking a year-over-year decrease of 49467.68%. This contributed to the annual value of -$1.0 million for FY2025, which is 49318.18% down from last year.
  • According to the latest figures from Q4 2025, AVITA Medical's Other Non Operating Income is $20000.0, which was up 10934.58% from -$2.8 million recorded in Q3 2025.
  • In the past 5 years, AVITA Medical's Other Non Operating Income registered a high of $6.3 million during Q4 2023, and its lowest value of -$2.8 million during Q3 2025.
  • Moreover, its 5-year median value for Other Non Operating Income was $28000.0 (2022), whereas its average is $453947.4.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 535000.0% in 2022, then plummeted by 109848.48% in 2025.
  • Quarter analysis of 5 years shows AVITA Medical's Other Non Operating Income stood at $16000.0 in 2021, then surged by 3556.25% to $585000.0 in 2022, then surged by 984.1% to $6.3 million in 2023, then plummeted by 103.37% to -$214000.0 in 2024, then skyrocketed by 109.35% to $20000.0 in 2025.
  • Its Other Non Operating Income stands at $20000.0 for Q4 2025, versus -$2.8 million for Q3 2025 and $2.5 million for Q2 2025.